1 Department of Medicine, 2 Department of Radiology, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan, Republic of China
Received 14 May 2003; revised 11 June 2003; accepted 11 August 2003
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Transarterial chemoembolization (TACE) and percutaneous acetic acid injection (PAI) are effective treatments for hepatocellular carcinoma (HCC). We have conducted a prospective study to compare the efficacy of sequential TACE and PAI (TACE-PAI) versus repeated PAI therapy for HCC.
Patients and methods:
A total of 108 HCC patients with tumor size 5 cm were enrolled. Fifty-three patients were treated with TACEPAI and 55 patients were treated with PAI alone.
Results:
Objective responses were achieved in 72 of 80 nodules (90%) in the TACEPAI group compared with 51 of 62 nodules (82%) in the PAI group (P = 0.217) during 24 ± 10 months of follow-up. Patients in the TACEPAI group had a significantly lower cumulative tumor recurrence rate from the treated nodule (P = 0.004) or newly developed tumor elsewhere in liver (P = 0.010). Complete tumor necrosis in large (35 cm) HCCs was more frequently encountered in the TACEPAI group (64% versus 37%; P = 0.034). There was no significant survival difference between the two groups with small (3 cm) HCC (P = 0.569), whereas PAI therapy was an independent poor prognostic predictor [relative risk 3.0 (95% confidence interval 1.27.6); P = 0.017] in the large HCC group.
Conclusions:
Sequential therapy with TACE and PAI is superior to repeated PAI alone for patients with large HCC.
Key words: arterial embolization, hepatocellular carcinoma, liver cirrhosis, percutaneous acetic acid injection
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
For patients with unresectable disease, the goal of palliative treatment is to control symptoms and prolong survival [24]. TACE using iodized oil and chemotherapeutic agents combines the effect of targeted chemotherapy with that of ischemic necrosis induced by arterial embolization. It can be administered repeatedly and can prolong survival in patients with unresectable hypervascular HCC [11, 25, 26]. Several studies have reported that a combination of TACE and ultrasound-guided percutaneous ethanol injection was more effective and yielded a better survival rate compared with TACE alone [2729]. On the other hand, some reports suggest that by using 1550% acetic acid, percutaneous acetic acid injection (PAI) has stronger necrotizing power compared with that of pure ethanol [20, 21], and may be equally effective or even superior to ethanol injection in treating small HCC [19, 22]. However, the efficacy and survival benefit of sequential therapy using TACE and PAI have not been specifically assessed. To determine whether sequential therapy can achieve a better treatment response and prolong long-term survival, we have prospectively evaluated the therapeutic efficacy of sequential TACE and PAI compared with that of PAI alone in treating patients with unresectable HCC.
![]() |
Patients and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Treatment and follow-up
TACE was carried out according to Seldingers technique of arterial embolization [31]. The equipment used for selective common or proper hepatic artery angiography was LCN (GE Medical Systems, Waukesha, WI, USA) or Diagnost 3 (Philips, Amsterdam, The Netherlands). Hepatic arteriography and superior mesenteric arterial portovenography were performed to define the size and location of tumor nodules. During the sequential scanning of the liver, radiocontrast medium (Telebrix, Guerbet, Paris, France or Ultravist, Schering, Berlin, Germany) 100150 ml was injected using a power injector (CT9000 ADV; Liebel-Flarsheim, St Louis, MI, USA) to evaluate the vascularity of the tumor (tumor stain). The arteries supplying the tumor were catheterized superselectively followed by an infusion of a mixture of doxorubicin 2030 mg (Carlo Erba, Milan, Italy) and lipiodol 510 ml (Laboratoire Guerbet, Aulnay-Sous-Bois, France). The aim was to deliver a sufficient amount of emulsion to the tumoral areas without retrograde flow. Under fluoroscopic control, the feeding arteries were subsequently embolized with 23 mm strips of Gelfoam (Upjohn, Kalamazoo, MI, USA) until complete flow stagnation was achieved.
In the TACEPAI group, TACE was performed up to a maximum of three courses or discontinued when any of the following conditions developed: (i) faint or no tumor stain on hepatic angiography; (ii) feeding artery not accessible by catheter; and (iii) deterioration of liver function as reflected by an increase of >1 mg/dl in serum total bilirubin level and a decrease of >0.5 g/dl in serum albumin. A dynamic CT scan was performed 1 month after the completion of TACE, and PAI was then administered to the remaining viable part of the tumor nodule as reflected by a CT scan showing contrast enhancement in the arterial phase.
The equipment used for PAI was a commercially available ultrasound scanner with a puncture probe with guide device (Aloka, Tokyo, Japan). Sterile 50% acetic acid (Merck, Darmstadt, Gemany) was injected with a 22-gauge spinal needle [22]. Treatment was administered twice a week in an inpatient setting. Typically, one or two injections at a dose of 25 ml acetic acid were given during each treatment session. Acetic acid was slowly injected until the echogenic area appearing immediately after injection covered the entire tumor. After the injection was complete, the needle was left in place for 12 min to prevent reflux of acetic acid into the peritoneal cavity. Three to four sessions were given for lesions 3 cm and four to six sessions were given for lesions >3 and
5 cm. For patients with multiple tumors, PAI was performed first on the main tumor (one with the largest diameter), followed by treating the smaller ones until all tumors were successfully treated.
Post-treatment follow-up included ultrasound scan and measurement of serum AFP levels every 2 months and contrast-enhanced dynamic CT every 34 months. MRI and/or hepatic angiography were carried out as supplemental examinations. Treatment response was evaluated 1 month after the second treatment cycle of PAI in both the TACEPAI and PAI groups. Additional treatment cycles were administered once tumor recurrence or viable tumor was found. When patients developed a diffuse, infiltrative HCC, they were considered non-responsive and not treated.
Assessment of treatment
Objective responses accounted for complete (no neoplastic disease) and partial responses (reduction of total tumor load >50%) as defined by World Health Organization (WHO) criteria [32]. Complete tumor necrosis was defined as absence of a contrast-enhanced area on the CT scan and no tumor staining following angiography of the treated tumor. Detection of local residual disease was defined as a recurrent tumor within or adjacent to the treated tumor, and new nodular recurrence was defined as a recurrence elsewhere separate from the treated tumor. Residual or new tumors were detected by dynamic CT showing contrast enhancement during the arterial phase or hepatic angiography showing tumor staining. Primary and secondary end points for this study were patient survival and tumor recurrence, respectively.
Statistical methods and risk factor analysis
Assumptions were a 3-year survival of 40% in the PAI group and 70% in the TACEPAI group based on our and others previous series [1922]. Fifty patients were needed in each group to detect an increase in survival, with a two-sided type I error of 5% and a power of 80% (SPSS SamplePower 2.0).
All statistical analyses were carried out using SPSS for Windows, release 11.0.1 (SPSS, Chicago, IL, USA). Chi-square or Fishers exact tests (two-tailed) were used for categorical data, and MannWhitney ranked sum test was used for continuous data. The overall survival and cancer-free survival were estimated by the KaplanMeier method and compared with the log-rank test. Patient- and tumor-related variables including age, sex, underlying hepatitis, ChildPugh class, number and size of tumor, ascites, serum levels of albumin, bilirubin and AFP, prothrombin time ratio, history of esophageal varices bleeding or hepatic encephalopathy and treatment modality were included for analysis. Factors that were significant or marginally significant (P <0.1) in univariate survival analysis were entered into a Cox proportional hazard model to determine the risk ratios. For all tests, a value of P <0.05 was considered statistically significant.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
Survival analysis
The average follow-up period was 24 ± 10 months. The overall 1- and 3-year survival rates were 100% and 69% for the TACEPAI group and 96% and 32% for the PAI group, respectively (P = 0.008; Figure 1A). The independent prognostic factors predicting a poor survival were the presence of ascites {relative risk (RR) 6.3 [95% confidence interval (CI) 2.019.7]; P = 0.002} and a history of encephalopathy [RR 4.1 (95% CI 1.511.3); P = 0.007] in the Cox multivariate analysis; PAI treatment was associated with a poor survival at a marginal significance (P = 0.103).
|
Overall survival and cancer-free survival stratified by tumor size
For patients with small (3 cm) HCCs, there was no significant overall survival difference between the TACEPAI and PAI groups. The 1- and 3-year survival rates were 100% and 73% for the TACEPAI group and 100% and 49% for the PAI group, respectively (P = 0.569; Figure 2A). However, for patients with large (>3 cm) HCCs, the survival was significantly better in the TACEPAI group. The 1- and 3-year survival rates were 100% and 64% for the TACEPAI group and 90% and 22% for the PAI group, respectively (P = 0.003; Figure 2B). Multivariate survival analysis in this group indicated that a history of encephalopathy [RR 9.4 (95% CI 1.654.1); P = 0.012] and PAI treatment [RR 3.0 (95% CI 1.27.6); P = 0.017) were independent prognostic factors predicting a poor survival.
|
Side-effects
Transient fever, abdominal pain and elevation of liver enzymes were present in the majority of patients after TACE. Side-effects of PAI treatment were relatively mild. Most patients experienced transient mild to moderate local pain during or after acetic acid injection, which could be controlled with additional analgesics. No serious complications that necessitated intensive care were encountered with either therapy.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
It was reported that acetic acid has a strong ability to penetrate cells and can dissolve lipids and extract collagen from intra-tumoral septa and capsule that frequently contain viable cancer cells [20, 21]. Therefore, acetic acid is theoretically superior to ethanol in treating patients with HCC, since the texture of the tumor and its resistance to perfusion with ethanol may make percutaneous ethanol injection less effective [19]. In addition, PAI has the advantage of a reduced number of treatment sessions, as well as a smaller injected volume in each treatment course compared with that of percutaneous ethanol injection [22]. There has been only one study to date that has assessed the effect of PAI with or without previous TACE for large (>3 cm) HCC [21]. However, the case number in that report was too small to draw any firm conclusions. Our study included a larger patient population, which may allow for a comparison between the two groups of patients. We found that sequential TACEPAI was a safe procedure and may be considered as a treatment alternative for patients with 35 cm sized HCC.
Although both TACEPAI and PAI therapy may achieve a similar degree of objective response after treatment, large-sized tumor nodules showed complete necrosis more often in the TACEPAI group and thus this group had a lower recurrence rate. In this study, about two-thirds of patients eventually developed a tumor recurrence. Such a high rate of recurrence is not unusual and is possibly related to the multiple metachronous or unnoticed synchronous tumors that could not even be detected by highly sensitive imaging modalities [33]. Nevertheless, a high tumor recurrence rate is not a specific drawback of PAI or TACE, because it is also found in cirrhotic patients with HCC treated with any other modality, including surgical resection [3, 4]. Our results showed that sequential TACEPAI therapy could effectively delay the time interval to recurrence, especially in patients with large HCC. Another interesting finding of this study was that there was no significant difference in cancer-free survival between the two groups of patients with small (3 cm) HCC. In fact, a high rate of complete tumor necrosis has been achieved in both groups (83% versus 84% in the TACEPAI and PAI groups, respectively), indicating that PAI therapy alone may have similar therapeutic efficacy compared with that of combination therapy.
Tumor size has been shown to be an important prognostic predictor in HCC patients undergoing surgical resection [35], liver transplantation [6], TACE [7, 9] and percutaneous ethanol injection [1417]. When survival was stratified by tumor size, we found that treatment modality was not a prognostic predictor in the small (3 cm) HCC group, whereas PAI therapy was a significant risk factor independently predicting a poor survival among the patients with large HCC. These findings were consistent with the result that patients with large HCC receiving sequential TACEPAI therapy less frequently developed a tumor recurrence.
In conclusion, sequential therapy using TACE and PAI may achieve a lower tumor recurrence rate and could prolong survival in patients with large HCC. For patients with small HCC, PAI alone is sufficient and there is no additional benefit of combination therapy with TACE. Careful pre-treatment patient evaluation and selection may provide a better clinical outcome.
![]() |
Acknowledgements |
---|
![]() |
Footnotes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2. Hussain SA, Ferry DR, El-Gazzaz G et al. Hepatocellular carcinoma. Ann Oncol 2001; 12: 161172.[Abstract]
3. Shirabe K, Kanematsu T, Matsumata T et al. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analysis. Hepatology 1991; 14: 802805.[ISI][Medline]
4. Nagasue N, Uchida M, Makino Y et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993; 105: 488494.[ISI][Medline]
5. Izumi R, Shimizu K, Li T et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994; 106: 720727.[ISI][Medline]
6. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999; 19: 311322.[ISI][Medline]
7. Ryder SD, Rizzi PM, Metivier E et al. Chemoembolizaton with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma. Gut 1996; 38: 125128.[Abstract]
8. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56: 918928.[ISI][Medline]
9. Takayasu K, Shima Y, Muramatsu Y et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with or without chemotherapeutic agents. Radiology 1987; 163: 345351.[Abstract]
10. Matsui O, Kadoya M, Yoshikawa J et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188: 7983.[Abstract]
11. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 11641171.[CrossRef][ISI][Medline]
12. Livraghi T, Giorgio A, Marin G et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101108.[Abstract]
13. Shiina S, Yasuda H, Muto H et al. Percutaneous ethanol injection in the treatment of liver neoplasms. Am J Roentgenol 1987; 149: 949952.[ISI][Medline]
14. Shiina S, Tagawa K, Niwa Y et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. Am J Roentgenol 1993; 160: 10231028.[Abstract]
15. Vilana R, Bruix J, Bru C et al. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992; 16: 353357.[ISI][Medline]
16. Lencioni R, Bartolozzi C, Caramella D et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: analysis of prognostic factors in 105 western patients. Cancer 1995; 76: 17371746.[ISI][Medline]
17. Kotoh K, Sakai H, Sakamoto S et al. The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy. Am J Gastroenterol 1994; 89: 194198.[ISI][Medline]
18. Huo TI, Huang YH, Wu JC et al. Survival benefit of cirrhotic patients with hepatocellular carcinoma treated by percutaneous ethanol injection as a salvage therapy. Scand J Gastroenterol 2002; 37: 350355.[CrossRef][ISI][Medline]
19. Ohnishi K, Yoshioka H, Ito S et al. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998; 27: 6772.[ISI][Medline]
20. Ohnishi K, Nomura F, Ito S et al. Prognosis of small hepatocellular carcinoma (<3 cm) after percutaneous acetic acid injection: study of 91 cases. Hepatology 1996; 23: 9941002.[ISI][Medline]
21. Ohnishi K, Yoshioka H, Ito S et al. Treatment of nodular hepatocellular carcinoma larger than 3 cm with ultrasound-guided percutaneous acetic acid injection. Hepatology 1996; 24: 13791385.[ISI][Medline]
22. Huo TI, Huang YH, Wu JC et al. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective controlled study. Scand J Gastroenterol 2003; 38: 770778.[ISI][Medline]
23. Livraghi T, Goldberg SN, Lazzaroni S et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655661.
24. Simonetti RG, Liberati A, Angiolini C et al. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8: 117136.[Abstract]
25. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 17341739.[CrossRef][ISI][Medline]
26. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429442.[CrossRef][ISI][Medline]
27. Tanaka K, Nakamura S, Numata K et al. Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization. Radiology 1992; 185: 457460.[Abstract]
28. Tanaka K, Nakamura S, Numata K et al. The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis. Cancer 1998; 82: 7885.[CrossRef][ISI][Medline]
29. Bartolozzi C, Lencioni R, Caramella D et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995; 197: 812818.[Abstract]
30. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 421430.[CrossRef][ISI][Medline]
31. Huang YS, Chiang JH, Wu JC et al. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol 2002; 97: 12231227.[CrossRef][ISI][Medline]
32. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207214.[ISI][Medline]
33. Rizzi PM, Kane PA, Ryder SD et al. Accuracy of radiology in detection of hepatocellular carcinoma before liver transplantation. Gastroenterology 1994; 107: 14251429.[ISI][Medline]